Mobic (Meloxicam)

Meloxicam works by reversibly inhibiting cyclooxygenase enzymes, especially COX‑2. This reduces the conversion of arachidonic acid into prostaglandins, which are key mediators of inflammation, pain, and fever. Lower prostaglandin levels lead to decreased swelling and pain in affected tissues.

The specific dose of Mobic is determined by the prescribing clinician based on the patient’s condition, severity, age, renal and hepatic function, and other individual factors. Healthcare professionals follow approved labeling and clinical guidelines to select an appropriate regimen.

Data on meloxicam use in pregnancy and lactation are limited. Generally, it is avoided unless the potential benefit justifies the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Mobic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature requirements) and necessary import documentation.

Mobic (meloxicam) offers a longer half‑life and greater COX‑2 selectivity than many traditional NSAIDs like ibuprofen, which may allow once‑daily dosing and potentially lower gastrointestinal risk. However, individual response varies, and clinicians consider efficacy, safety profile, patient comorbidities, and cost when selecting an NSAID.

Mobic tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture, heat and direct sunlight, and keep out of reach of children.

Mobic is taken orally, usually with a glass of water. It can be taken with or without food, but patients who experience stomach upset may benefit from taking it with meals. The exact administration schedule is set by the prescribing clinician.

Serious risks include gastrointestinal ulceration or bleeding, severe liver injury, and acute kidney impairment. Cardiovascular events such as heart attack or stroke may also occur, especially in patients with existing heart disease. Patients should be monitored closely for any signs of these complications.

Mobic should be avoided in individuals with known hypersensitivity to meloxicam or other NSAIDs, those with active gastrointestinal bleeding, severe renal or hepatic impairment, uncontrolled hypertension, and in patients in the third trimester of pregnancy. Clinicians must assess each patient’s medical history before prescribing.